Tổng quan về liệu pháp điều trị ung thư nhắm mục tiêu

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314–24. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 1997; 57: 5246–53. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 2000; 18: 1124–34. Hasinoff BB, Chee GL, Thampatty P, Allan WP, Yalowich JC. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs 1999; 10: 47–54. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008; 77: 311–9. Sorokin P. Mylotarg approved for patients with CD33+ acute myeloid leukemia. Clin J Oncol Nurs 2000;4:279–80. Jacobs SA. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects. Biologics 2007; 1: 215–27. Vitolo U, Ladetto M, Boccomini C, Evangelista A, Gamba E, Russo E, et al. Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). Blood 2011; 118: 352–53. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. Immunocytokines: A promising approach to cancer immunotherapy. Pharmacol Ther 1998; 80: 277–92. Kerr DE, Vrudhula VM, Svensson HP, Siemers NO, Senter PD. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. Bioconjug Chem 1999; 10: 1084–89. Wolfe LA, Mullin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, et al. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: In vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconjug Chem 1999; 10: 38–48. Kawakami K, Nakajima O, Morishita R, Nagai R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. Thescientific World Journal 2006; 6: 781–90. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47–58. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibodychemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64: 7995–8001. Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther 2000; 7: 224–31. Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther 1999; 10: 235–48. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Investig 2000; 105: 1161–67. Riggs CD. Meiotin-1: the meiosis readiness factor? BioEssays 1997; 19: 925–31. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Ther 1998; 9: 1261–73. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ. Gene-directed enzyme prodrug therapy. Bioconjug Chem 1998; 9: 4–22. Friedlos F, Court S, Ford M, Denny WA, Springer C. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther1998; 5: 105–12. Clark AJ, Iwobi M, Cui W, Crompton M, Harold G, Hobbs S, et al. Selective cell ablation in transgenic mice expressing E-coli nitroreductase. Gene Ther 1997; 4: 101–10. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase CB 1954 enzyme prodrug system is due to a cell-permeable metabolite. Human Gene Ther 1997; 8: 709–17. McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E-coli nitroreductase and CB1954. Gene Ther 1998; 5: 1061–69. Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Des 1999; 14: 461–72. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447–52. Warrington KH, Teschendorf C, Cao LG, Muzyczka N, Siemann DW. Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. Int J Radia Oncol Biol Phys 1998; 42: 909–12. Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, et al. gamma-Rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther 2001; 8: 99–106. Fukui T, Hayashi Y, Kagami H, Yamamoto N, Fukuhara H, Tohnai I, et al. Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector. Oral Oncol 2001; 37: 211–5. Westphal EM, Ge JQ, Catchpole JR, Ford M, Kenney SC. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: Induction of bystander killing in vitro and in vivo. Cancer Gene Ther 2000; 7: 97–106. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395–99. Rigg A, Sikora K. Genetic prodrug activation therapy. Mol Med Today 1997; 3: 359–66. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GWH, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180–89. Syrigos KN, Epenetos AA. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations. Anticancer Res 1999; 19: 605–13. Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother Pharmacol 1997; 40: 277–84. Syrigos KN, Rowlinson-Busza G, Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer 1998; 78: 712–19. Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 1998; 41: 3572–81. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999; 59: 3998–4003. Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, van den Meulen-Mulleman IH, Pinedo HM, et al. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood 1998; 92: 184–90. Mason DW, Williams AF. The Kinetics of Antibody-Binding to Membrane-Antigens in Solution and at the Cell-Surface. Biochem J 1980; 187: 1–20. Martin J, Stribbling SM, Poon GK, Begent RHJ, Napier M, Sharma SK, et al. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997; 40: 189–201. Denny WA, Wilson WR. The design of selectively-activated anticancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol 1998; 50: 387–94. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. Blood 1988; 72: 567–72. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–17. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012; 52: 549–73. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693–703. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3:711–16. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002; 297: 63–4. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077–80; discussion 80. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007; 25: 209–16. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2: 689–700. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med 2011; 364: 340–50. Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell 2011; 147: 26–31. De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol 2012; 6: 111–27. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253–61. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007; 13: 7264–70. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051–60. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387–90. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintas-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 2012; 118: 293–9. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011; 1: 248–59. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968–U370. Nazarian R, Shi HB, Wang Q, Kong XJ, Koya RC, Lee H, et al. Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973–U377. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446: 815–19. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2008; 30: 782–89. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 2011; 3: 381–94. Vanniasinghe AS, Bender V, Manolios N. The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis. Semin Arthritis Rheum 2009; 39: 182–96. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J Control Release 2010; 144: 324–31. Stratton MR. Exploring the Genomes of Cancer Cells: Progress and Promise. Science 2011; 331: 1553–58. MacConaill LE, Garraway LA. Clinical Implications of the Cancer Genome. J Clin Oncol 2010; 28: 5219–27. Kitano H. Cancer robustness - Tumour tactics. Nature 2003; 426: 125–25.